These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39257586)

  • 21. The contributions of vaccination and natural infection to the production of neutralizing antibodies against the SARS-CoV-2 prototype strain and variants.
    Xie H; Zhang J; Bai S; Lv M; Li J; Chen W; Suo L; Chen M; Zhao W; Zhou S; Wang J; Zhang A; Ma J; Wang F; Yan L; Li D; Wu J
    Int J Infect Dis; 2024 Jul; 144():107060. PubMed ID: 38670482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
    Angkasekwinai N; Niyomnaitham S; Sewatanon J; Phumiamorn S; Sukapirom K; Senawong S; Toh ZQ; Umrod P; Somporn T; Chumpol S; Ritthitham K; Jantraphakorn Y; Srisutthisamphan K; Chokephaibulkit K
    Asian Pac J Allergy Immunol; 2024 Sep; 42(3):276-289. PubMed ID: 37466962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine.
    Yisimayi A; Song W; Wang J; Jian F; Yu Y; Chen X; Xu Y; An R; Wang Y; Wang J; Sun H; Wang P; Yu L; Shao F; Jin R; Shen Z; Wang Y; Cao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2412623. PubMed ID: 39360822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
    Wang F; Huang B; Deng Y; Zhang S; Liu X; Wang L; Liu Q; Zhao L; Tang L; Wang W; Wang X; Ye F; Hu W; Yang H; Wang S; Ren J; Liu X; Wang C; Guan X; Wang R; Zheng Y; Zhang X; Zheng H; Wu D; An Z; Xu W; Rodewald LE; Gao GF; Yin Z; Tan W
    BMC Med; 2023 Jul; 21(1):233. PubMed ID: 37400857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.
    Zhang XS; Windau A; Meyers J; Yang X; Dong F
    Microbiol Spectr; 2024 Oct; 12(10):e0060524. PubMed ID: 39162540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China.
    Mai W; Shen J; Ma F; Zhu J; Chen L; Lei Y; Yu P; Niu C; Wang F; Yan S; Mai X; He P; Liao L; Xiong X; Zheng Y; Liu Q; Huang Y; Wang Q; Liang J; Ji T
    Vaccine; 2024 Aug; 42(21):126108. PubMed ID: 39048466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
    Poh XY; Torres-Ruesta A; Yoong T; Wong N; Tan CW; Rouers A; Chavatte JM; Goh YS; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Neo V; Kam IKJ; Huang Y; Hor PX; Loh CY; ; Yeoh AY; Lim DRX; Chia W; Ren EC; Lin RTP; Fong SW; Renia L; Lye DC; Wang LF; Ng LFP; Young BE
    Vaccine; 2024 Nov; 42(25):126275. PubMed ID: 39241318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
    Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM
    Front Immunol; 2024; 15():1372193. PubMed ID: 38812507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omicron neutralization character in patients with breast cancer and liver cancer after the nationwide omicron outbreak.
    Zhang S; Tang L; Bao C; Wang S; Li B; Huang L; Song H; Fu J; Xu Z; Meng F; Cao L; Gao Y; Yuan Y; Chen Y; Yuan J; Zhou C; Li F; Qin L; Guo Y; Zhang C; Song J; Fan X; Jiang Z; Wang FS; Xu R
    Cancer Med; 2024 Jun; 13(11):e7304. PubMed ID: 38826094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.
    Yadav PD; Sardana V; Deshpande GR; Shinde PV; Thangaraj JWV; George LS; Sapkal GN; Patil DY; Sahay RR; Shete AM; Joshi M; Murhekar M; Godbole S; Gupta N; Prakash S; Rathore M; Ujjainiya R; Singh AP; Mishra A; Dash D; Chaudhary K; Sengupta S;
    Indian J Med Res; 2024 Feb; 159(2):223-231. PubMed ID: 38517215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic changes of neutralizing antibody and memory T cell responses six months post Omicron XBB reinfection.
    Zhao XJ; Li XL; Zhang S; Chen JJ; Zhao WC; Wu NN; Wang RJ; Xu Q; Lv CL; Jiang BG; Wang GL; Fang LQ
    Front Immunol; 2024; 15():1477721. PubMed ID: 39434881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants.
    Luo M; Zhou R; Tang B; Liu H; Chen B; Liu N; Mo Y; Zhang P; Lee YL; Ip JD; Wing-Ho Chu A; Chan WM; Man HO; Chen Y; To KK; Yuen KY; Dang S; Chen Z
    EBioMedicine; 2024 Oct; 108():105354. PubMed ID: 39341153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.
    Wang Q; Mellis IA; Guo Y; Gherasim C; Valdez R; Gordon A; Ho DD; Liu L
    Cell Rep Med; 2024 Sep; 5(9):101701. PubMed ID: 39208800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection.
    Jiang XL; Song XD; Shi C; Yang GJ; Wang XJ; Zhang YW; Wu J; Zhao LX; Zhang MZ; Wang MM; Chen RR; He XJ; Dai EH; Gao HX; Shen Y; Dong G; Wang YL; Ma MJ
    Cell Rep; 2024 Jul; 43(7):114387. PubMed ID: 38896777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.